Dow Up1.21% Nasdaq Up1.08%

More On TKM.TO



News & Info


Analyst Coverage


  • Major Holders
  • Insider Transactions
  • Insider Roster


Tekmira Pharmaceuticals Corporation (TKM.TO)

21.65 Down 0.12(0.55%) 9:40AM EDT
ProfileGet Profile for:
Tekmira Pharmaceuticals Corporation
100-8900 Glenlyon Parkway
Burnaby, BC V5J 5J8
Canada - Map
Phone: 604-419-3200
Fax: 604-419-3201

Index Membership:N/A
Full Time Employees:N/A

Business Summary 

Tekmira Pharmaceuticals Corporation, a biopharmaceutical company, focuses on the research and development of RNA interference therapeutics; and provides lipid nanoparticle delivery technology to pharmaceutical partners in Canada. Its pipeline products include TKM-PLK1, an oncology product platform that is in Phase I/II clinical trials, which targets polo-like kinase 1, a protein involved in tumor cell proliferation and a validated oncology target; and TKM-HBV, which is in Phase I clinical trial to eliminate surface antigen expression in the chronically infected patients. The company is also involved in developing TKM-Ebola, an anti-ebola viral therapeutic that is in Phase I clinical trial; and TKM-Marburg to treat Marburg infections. In addition, its preclinical product candidate includes TKM-ALDH2 for the treatment of alcohol use disorder. The company has strategic alliances with Alnylam Pharmaceuticals, Inc.; Acuitas Therapeutics Inc.; Spectrum Pharmaceuticals, Inc.; Monsanto Company; Marina Biotech, Inc./Arcturus Therapeutics, Inc.; Merck & Co., Inc.; Bristol-Myers Squibb Company; and U.S. National Institutes of Health. Tekmira Pharmaceuticals Corporation is headquartered in Burnaby, Canada.

Key Statistics

Company Websites 
Home Page
Search Yahoo! for:
More on Tekmira Pharmaceuticals Corporation

Key Executives 
Dr. Mark J. Murray Ph.D., 65
Chief Exec. Officer, Pres and Director
Mr. Bruce G. Cousins C.A., CPA, 53
Chief Financial Officer, Principal Accounting Officer and Exec. VP
Dr. Ian MacLachlan Ph.D., 50
Chief Technical Officer and Exec. VP
Dr. Peter Lutwyche Ph.D.,
Sr. VP of Pharmaceutical Devel.
Dr. Michael J. Abrams Ph.D., 58
Chief Discovery Officer and Exec. VP
Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in CAD.